Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus XENON XE 133 V S S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus XENON XE 133 V S S.
INDIUM IN 111 CHLORIDE vs XENON XE 133-V.S.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Xenon Xe-133 is a radioactive gas that emits beta and gamma radiation. It distributes to the lungs and is used for ventilation-perfusion imaging. Its mechanism is based on regional distribution in the lungs, reflecting ventilation. It does not have pharmacological activity.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
5-10 mCi (185-370 MBq) inhaled as a single dose for pulmonary ventilation imaging.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Terminal elimination half-life of approximately 3.5 minutes, corresponding to rapid washout from lungs following cessation of inhalation.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Eliminated almost entirely via exhalation through the lungs (>95%); negligible renal or biliary/fecal excretion.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical